Ruti Aga: Marathon Runner Handed Six-Year Ban Over Fake Prescription Issued by Family Member

Ethiopian marathon runner Ruti Aga has been banned for six years by the Athletics Integrity Unit (AIU). The case is unusual because the central question is not the substance itself but the paperwork around it. According to the AIU's statement issued on Thursday, the prescription Aga submitted for the treatment of a knee injury was not issued by a registered physician but was produced by a member of her own family. The clinic named on the prescription did not exist, and the person who described himself as a doctor held no medical registration. The arithmetic of the sanction is straightforward and is the key to the entire case: two years for the presence of a prohibited substance, plus four years for tampering — submitting fabricated documents and giving misleading statements during the investigation — for a total of six years. Both periods run concurrently from 10 September, the date from which Aga had already been provisionally suspended. The backdating is technically a procedural benefit but delivers no real relief, because time served under provisional suspension counts against the ban anyway. One element of the case has been widely misreported. The substance found in Aga's sample was methylprednisolone, described in several reports as a "prohibited steroid" that WADA classifies as performance-enhancing. That is technically incorrect. Methylprednisolone is a glucocorticoid, listed under class S9 of the WADA Prohibited List, not an anabolic steroid under S1. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only when administered by injection, orally or rectally. A therapeutic injection given out-of-competition is entirely legal. The consequence is decisive: the case hinges on the route of administration and the timing relative to the competition, not on "steroid use." That is precisely why the case points to a self-inflicted error. Had genuine medical records existed, had the timing been managed correctly, and had a Therapeutic Use Exemption been sought, the case would in all likelihood never have arisen. Instead a document was fabricated that failed three independent verification checks: the clinic did not exist, the "doctor" was unregistered, and the claim that an old prescription pad from a former workplace had been used was explicitly disowned by the clinic in question. It should be stated clearly that the name, the year and the finishing time of the March half marathon in China at which the sample was collected have not been disclosed in any official statement. All that is known is that Aga won the race and that the sample taken afterwards returned an adverse finding. Her personal best, her splits, the strength of the field and the prize money involved are all undisclosed, which makes any technical performance assessment impossible. The only performance-relevant fact available is that she won — which implies a World Athletics Label-tier race with a functioning testing regime. The most significant consequence is that a six-year ban effectively ends the career of a 32-year-old. If the ban runs six years from 10 September, a return would come at roughly 38 — an age at which, given the extraordinary depth of Ethiopian women's marathon running, an athlete with a doping record is essentially unselectable. On paper the ban is six years; in practice it is a career-ending sanction. Notably, the substance at the centre of the case is not one associated with endurance performance enhancement. Glucocorticoids reduce inflammation and mask pain; they are not stimulants. That does not make their use legitimate, but it does mean this case should not be compared with anabolic steroid or blood-doping violations. The two-year presence sanction indicates the panel treated it as a Specified Substance case, where intent must be established and where a no-significant-fault reduction is available. The separate four-year sanction is the standard Code penalty for tampering. The structure of the sanction reveals something further. Two years for presence, with no aggravation, implies the panel did not find intent proven. But it treated the tampering as fully culpable, because that finding rests on documents and is difficult to challenge. There is an apparent paradox here: forged documentation is itself evidence of an intent to conceal, yet it did not escalate the presence sanction. The likely explanation is that tampering and presence are treated as distinct violations with distinct penalties rather than being aggregated. The most human and most troubling dimension concerns the knee injury Aga cited in her defence. Knee pathology is among the most common injuries in distance running, and intra-articular or peri-articular glucocorticoid injection for knee synovitis is standard sports-medicine practice for elite women marathoners. That plausibility is exactly what makes the forgery decisive: a genuinely documented treatment would have been defended with real records. What emerged instead was a clinic that existed only on paper, a physician who was a family member with no registration, and a prescription pad disowned by the clinic whose name it bore. This is not merely an individual lapse. It signals a failure of medical governance inside East African road-running entourages. An athlete good enough to have won a World Marathon Major appears to have had no credentialed team physician, no TUE infrastructure and no formal advisory structure. When injury strikes, the cheapest and easiest route is to suppress the pain and keep racing, because visible injury directly threatens appearance-fee income. In that structure, a forged prescription is not a sudden decision but the logical endpoint of a long-standing informal treatment culture. The knee problem may well be chronic rather than a single event; the attempt to manufacture a paper trail suggests repeated informal treatment that required documentation only once scrutiny intensified. It is also unknown whether the family member acted alone or with the knowledge of an agent or manager. The AIU statement names only the family member, and whether the entourage was investigated has not been disclosed. In career terms the picture divides in two. On one side stands the 2026 Tokyo Marathon title, still on the record, along with three second-place finishes at World Marathon Majors. External figures, pending independent verification, place her best at roughly 2:18:34 for second in Berlin 2026 and 2:20:40 for victory in Tokyo 2026 — the marks of a genuinely elite marathoner. On the other side sits a ban that makes her commercially radioactive in a sport where distance-running sponsorship is already thin. The year of the March race, and therefore the precise scope of disqualification, has not been stated. Standard AIU practice is automatic disqualification of the competition at which the sample was collected, including prize money, together with forfeiture of ranking points accrued thereafter. Results before that date — including the 2026 Major title — are not automatically annulled absent a finding of earlier use, and no such finding has been made public. Competitively, the impact is nil. Ethiopia's women's marathon depth is so extreme that even a 2:18 performer is not automatically selectable; a world-record-class top cohort, Kenya's championship-conversion strength and an essentially limitless talent pipeline mean one athlete's removal does not register in the selection calculus. Her three Major second places were commercial-tier results, not championship conversions. What is shifting is not the competitive landscape but the enforcement landscape. Tampering cases are clustering in AIU road-running files, which suggests the enforcement frontier has moved from detection to document verification. Aga's case is not an outlier; it belongs to a recognisable family of East African road-racing cases in which an initial substance violation is compounded by a fabricated explanation, doubling the sanction. There is also a geographic dimension: China's label-race circuit has long been a lucrative, low-risk income tier for East African marathoners between Majors — large appearance fees, few races, limited competitive pressure. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races, and more cases of this profile are likely, because the same informal medical networks serve many athletes in the same training clusters. On the rules, the case was pursued under the World Athletics Anti-Doping Rules, enforced by the AIU and applying the WADA Code (2026) and Prohibited List. Two violations were established: presence of an S9 glucocorticoid in-competition, and tampering through the submission of a forged prescription and misleading statements during interview. Technical competition rules, eligibility questions and equipment compliance are not implicated. One element sits outside AIU jurisdiction: document forgery may constitute a criminal offence, and referral to national authorities is possible, though nothing was said about it. The greatest tragedy of the case is that a legitimate defence existed. Because S9 substances are prohibited in-competition only, the questions that mattered were when the injection was given and by what route. A road race's testing window opens at 23:59 the day before the race, so an injection given sufficiently earlier, properly documented, would not have produced a presence violation at all — and even if it had, a no-fault or no-significant-fault argument could have reduced the sanction sharply, with no tampering charge whatsoever. In other words, the athlete destroyed the one defence that could have worked. An appeal remains technically open. The window to the Court of Arbitration for Sport is typically about 21 days from the reasoned decision, but a document-based forgery finding is extremely hard to overturn, so the appeal risk is live but of limited practical value. The larger and more uncomfortable question is proportionality. A six-year ban for a substance with no proven endurance benefit is a striking outcome, and it will be cited both as evidence of AIU rigour and as evidence of inconsistent enforcement against African road runners — particularly when the case originated in a gap in medical documentation that an athlete with a wealthier management structure could easily have closed. Three lessons emerge. First, medical documentation matters as much as training data; hiding injury is now the fastest route to career termination. Second, TUE infrastructure must be institutionalised rather than left to informal entourages, because where no formal structure exists, forgery becomes the natural option. Third, substance classes must be understood and reported accurately: glucocorticoids and anabolic steroids are not the same thing, and judging them on the same scale is not fair. Ruti Aga's name will now be remembered in two ways: as a runner who won a Major in Tokyo and finished second at three more, and as a runner who ended her remaining career herself through a knee injury and a forged prescription. The second sentence will be heard more loudly — and that is the saddest truth in this story.